Efficacy of propiverine hydrochloride extended release (ER) 45 mg in patients with neurogenic detrusor overactivity: an active-controlled single center crossover trial

Trial Profile

Efficacy of propiverine hydrochloride extended release (ER) 45 mg in patients with neurogenic detrusor overactivity: an active-controlled single center crossover trial

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2014

At a glance

  • Drugs Propiverine (Primary)
  • Indications Neurogenic bladder; Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Apogepha
  • Most Recent Events

    • 28 Jan 2014 According to European Clinical Trials Database record, status changed from recruiting to completed.
    • 11 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top